🎉 M&A multiples are live!
Check it out!

TScan Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for TScan Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

TScan Therapeutics Overview

About TScan Therapeutics

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.


Founded

2018

HQ

United States of America
Employees

195

Website

tscan.com

Financials

LTM Revenue $4.0M

LTM EBITDA -$125M

EV

-$123M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

TScan Therapeutics Financials

TScan Therapeutics has a last 12-month revenue of $4.0M and a last 12-month EBITDA of -$125M.

In the most recent fiscal year, TScan Therapeutics achieved revenue of $2.8M and an EBITDA of -$120M.

TScan Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See TScan Therapeutics valuation multiples based on analyst estimates

TScan Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $21.0M $2.8M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$80.1M -$120M XXX XXX XXX
EBITDA Margin -381% -4252% XXX XXX XXX
Net Profit -$66.2M -$89.2M XXX XXX XXX
Net Margin -315% -3168% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

TScan Therapeutics Stock Performance

As of April 15, 2025, TScan Therapeutics's stock price is $1.

TScan Therapeutics has current market cap of $70.2M, and EV of -$123M.

See TScan Therapeutics trading valuation data

TScan Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$123M $70.2M XXX XXX XXX XXX $-1.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

TScan Therapeutics Valuation Multiples

As of April 15, 2025, TScan Therapeutics has market cap of $70.2M and EV of -$123M.

TScan Therapeutics's trades at -30.6x LTM EV/Revenue multiple, and 1.0x LTM EBITDA.

Analysts estimate TScan Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for TScan Therapeutics and 10K+ public comps

TScan Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$123M XXX XXX XXX
EV/Revenue -43.5x XXX XXX XXX
EV/EBITDA 1.0x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TScan Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

TScan Therapeutics Valuation Multiples

TScan Therapeutics's NTM/LTM revenue growth is 83%

TScan Therapeutics's revenue per employee for the last fiscal year averaged $14K, while opex per employee averaged $0.7M for the same period.

Over next 12 months, TScan Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate TScan Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for TScan Therapeutics and other 10K+ public comps

TScan Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -87% XXX XXX XXX XXX
EBITDA Margin -4252% XXX XXX XXX XXX
EBITDA Growth 49% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -4169% XXX XXX XXX XXX
Revenue per Employee $14K XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 1050% XXX XXX XXX XXX
R&D Expenses to Revenue 3812% XXX XXX XXX XXX
Opex to Revenue 4888% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

TScan Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

TScan Therapeutics M&A and Investment Activity

TScan Therapeutics acquired  XXX companies to date.

Last acquisition by TScan Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . TScan Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by TScan Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About TScan Therapeutics

When was TScan Therapeutics founded? TScan Therapeutics was founded in 2018.
Where is TScan Therapeutics headquartered? TScan Therapeutics is headquartered in United States of America.
How many employees does TScan Therapeutics have? As of today, TScan Therapeutics has 195 employees.
Who is the CEO of TScan Therapeutics? TScan Therapeutics's CEO is Dr. Gavin MacBeath, PhD.
Is TScan Therapeutics publicy listed? Yes, TScan Therapeutics is a public company listed on NAS.
What is the stock symbol of TScan Therapeutics? TScan Therapeutics trades under TCRX ticker.
When did TScan Therapeutics go public? TScan Therapeutics went public in 2021.
Who are competitors of TScan Therapeutics? Similar companies to TScan Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of TScan Therapeutics? TScan Therapeutics's current market cap is $70.2M
What is the current revenue of TScan Therapeutics? TScan Therapeutics's last 12-month revenue is $4.0M.
What is the current EBITDA of TScan Therapeutics? TScan Therapeutics's last 12-month EBITDA is -$125M.
What is the current EV/Revenue multiple of TScan Therapeutics? Current revenue multiple of TScan Therapeutics is -30.6x.
What is the current EV/EBITDA multiple of TScan Therapeutics? Current EBITDA multiple of TScan Therapeutics is 1.0x.
What is the current revenue growth of TScan Therapeutics? TScan Therapeutics revenue growth between 2023 and 2024 was -87%.
Is TScan Therapeutics profitable? Yes, TScan Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.